Given its critical role in T-cell signaling, interleukin-2–inducible kinase (ITK) is an appealing
therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, …

Targeted therapy with imatinib in chronic myeloid leukemia (CML) prompted a new treatment
paradigm. Unlike CML, chronic lymphocytic leukemia (CLL) lacks an aberrant fusion …

Importance The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with
chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and …

By synergistically combining additive and subtractive processes within a single workstation,
the relative merits of each process may be harnessed. This facilitates the manufacture of …

Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic
lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon …

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting
Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance …

Purpose Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features
achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically …

Tetraspanins are commonly believed to act only as "molecular facilitators," with no direct
role in signal transduction. We herein demonstrate that upon ligation, CD37, a tetraspanin …

Ibrutinib represents a therapeutic advance in chronic lymphocytic leukemia (CLL) but as
monotherapy produces few complete remissions in previously treated patients. Anti-CD20 …

Purpose Chemoimmunotherapy has been the standard of care for chronic lymphocytic
leukemia (CLL). However, the introduction of B-cell receptor (BCR) kinase inhibitors such as …